Zobrazeno 1 - 10
of 20
pro vyhledávání: ''
Autor:
Walburgis Brenner, Marco Johannes Battista, Amelie Loewe, Anne-Sophie Heimes, R Schwab, Annette Hasenburg, Slavomir Krajnak, Marcus Schmidt
Publikováno v:
Anticancer Research. 41:1243-1250
Background/aim Breast cancer (BC) may be affected by diabetes and anti-diabetic medication, as well as its therapeutic agents. Low-dose metronomic chemotherapy (LDMC) is an available treatment option in BC. We investigated the impact of insulin on lo
Publikováno v:
Anticancer Research. 40:6699-6712
Background/aim There is no established standard chemotherapy after administration of the combination endocrine plus CDK4/6 inhibitor therapy for luminal-type breast cancer. We used patient-derived xenograft (PDX) models to determine the antitumor act
Autor:
Yoichi Naito, Takehiro Nakao, Kumi Niguma, Chikako Funasaka, Toru Mukohara, Toshikatsu Kawasaki, Hiromichi Nakajima, Kenichi Harano, Kanako Mamishin, Gakuto Ogawa, Ako Hosono, Saeko Sakaeda, Yoko Fukasawa, Shota Kusuhara, Nobuaki Matsubara, Chihiro Kondoh, Shogo Nomura, Kaede Baba, Takahiro Kogawa
Publikováno v:
Anticancer research. 41(12)
BACKGROUND/AIM To maximize the effect of perioperative chemotherapy in breast cancer, it is critical to keep the relative dose intensity (RDI) high. While bi-weekly doxorubicin and cyclophosphamide, dose-dense AC (ddAC), instead of tri-weekly convent
Autor:
Mayuko Miki, Koichi Hirokaga, Misao Soyama, Takuma Onoe, Kazuki Hashimoto, Koji Matsumoto, Minori Arase, Hideki Sakai, Meiko Nishimura, Shintaro Takao, Kaori Tane, Sayuri Watanabe
Publikováno v:
Anticancer Research. 39:4379-4383
Background/aim Dose-dense doxorubicin and cyclophosphamide (ddAC) followed by dose-dense paclitaxel (ddP) (ddAC-P) has improved disease-free survival of patients with breast cancer. The aim of this study was to evaluate the safety and relative dose i
Publikováno v:
Anticancer Research. 39:1875-1882
BACKGROUND/AIM We investigated the correlation between texture features on apparent diffusion coefficient (ADC) maps and histological vascular parameters of FN13762 rat breast cancers after antiangiogenic therapy. MATERIALS AND METHODS FN13762 cancer
Autor:
Kenji Tezuka, Kosei Hirakawa, Shigehito Yamagata, Mao Tokumoto, Minoru Takada, Takeo Nishimori, Katsumi Ikeda, Shinya Tokunaga, Hidemi Kawajiri, Yoshinari Ogawa, Yoko Mizuyama, Takeshi Sunami, Tsutomu Takashima, Shinichiro Kashiwagi, Masaichi Ohira, Tetsuro Ishikawa, Shinzoh Kudoh, Satoru Noda, Shigehiko Nishimura
Publikováno v:
Anticancer Research. 39:2053-2059
Aim This study was conducted in order to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus trastuzumab followed by 5-fluorouracil/ epirubicin/cyclophosphamide (FEC) in a neoadjuvant chemotherapy (NAC) set
Autor:
Takayuki Matsuda, Hiroshi Koyama, Nobuyuki Tsunoda, Koichi Sakaguchi, Kazuyoshi Onishi, Akira Sakuyama, Katsuhiko Nakatsukasa, Hiroki Tanaka, Tetsuya Taguchi, Masahide Yamaguchi, Yuji Yoshino, Makoto Kato, Takashi Kikuchi, Ikuya Fujiwara, Mie Onishi
Publikováno v:
Anticancer Research. 38:4073-4081
Background/aim Eribulin mesylate has been approved for advanced or metastatic breast cancers subjected to at least two previous chemotherapy regimens. The present multicenter, phase II, single-arm study assessed the efficacy and safety of a first-lin
Autor:
Tsunehiro Nishi, Takao Kato, Masashi Takeuchi, Munechika Tsuji, Sotaro Akatsuka, Atsushi Fukuuchi, Daisuke Ota
Publikováno v:
Anticancer research. 39(12)
Background/aim The objective of this phase I study was to determine the maximum-tolerated dose (MTD) and recommended dose (RD) of combination therapy with weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and cyclophosphamide (CPA) in met
Autor:
Christos, Damaskos, Nikolaos, Garmpis, Serena, Valsami, Michael, Kontos, Eleftherios, Spartalis, Theodoros, Kalampokas, Emmanouil, Kalampokas, Antonios, Athanasiou, Demetrios, Moris, Afrodite, Daskalopoulou, Spyridon, Davakis, Gerasimos, Tsourouflis, Konstantinos, Kontzoglou, Despina, Perrea, Nikolaos, Nikiteas, Dimitrios, Dimitroulis
Publikováno v:
Anticancer Research. 37:35-46
With a lifetime risk estimated to be one in eight in industrialized countries, breast cancer is the most frequent type of cancer among women worldwide. Patients are often treated with anti-estrogens, but it is common that some tumors develop resistan
Publikováno v:
Anticancer Research. 36:5849-5858
Clinical trials are in progress on AZD5363, an inhibitor of protein kinase B (AKT), to assess its effects on the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Cells treated with AKT inhibitors have been reported t